Navigation Links
AMIHOT II trial data presented at TCT
Date:10/23/2007

Late-breaking data presented at TCT 2007, the scientific symposium of the Cardiovascular Research Foundation (CRF), show that an infusion of blood that is supersaturated with oxygen (SSO2) can reduce the amount of damaged heart muscle following a heart attack.

Despite successful reperfusion or restoration of blood flow to the heart with angioplasty following a heart attack there is often an area of infarction, or damaged heart muscle caused by the death of cells due to the interruption of oxygen carrying blood.

In the AMIHOT II trial, investigators led by Gregg W. Stone, MD, Chairman, Cardiovascular Research Foundation and Professor of Medicine, Columbia University Medical Center sought to determine the efficacy and safety of infusing SSO2 into the previously blocked artery after an angioplasty procedure.

Among high-risk patients with acute anterior myocardial infarction (heart attack) undergoing successful angioplasty within 6 hours of symptom onset, infusion of SSO2 into the myocardial infarct territory results in a significant reduction in the size of the 'infarct zone, the amount of damaged heart tissue, Stone said.

The AMIHOT II trial was conducted with 304 patients randomized at 20 sites in four countries.

Data from the study show that the size of the infarct zone was 6.5 percent lower in the patients treated with SSO2 than in control patients who did not receive the therapy.

In addition, at 30 days after the treatment, the rates of Major Adverse Cardiac Events (MACE) were statistically equivalent between the two groups.


'/>"/>

Contact: Irma Damhuis
idamhuis@crf.org
917-558-5180
Cardiovascular Research Foundation
Source:Eurekalert

Page: 1

Related medicine news :

1. Man against HIV – new vaccine ready for human trials
2. FDA approves Phase 0 trial which tests experimental drugs on humans
3. Male contraceptive in trial
4. How do patients benefit of clinical trials
5. Glenmark’s new molecule to go through trial
6. Clinical trials need to be more frank
7. First head-to-head trials of once weekly Fosamax and Actonel therapies
8. Hormone Replacement Therapy increases the risk of endometrial cancer
9. Atrial fibrillation predicts for acute ischaemic stroke
10. Spray on contraceptive clears Phase I trial
11. The Indian Government has given the nod to conduct Human volunteer trials inorder to develop preventive AIDS vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... ... 2017 , ... SignatureCare Emergency Center – South Austin is treating both adult ... day. , The Emergency Room opened early March, making it the ... now and things are running smoothly,” said Aaron Braun, SignatureCare Emergency Center’s Chief Medical ...
(Date:7/24/2017)... Kansas City, MO (PRWEB) , ... July 24, 2017 , ... ... for the acclaimed Saint Luke’s Marion Bloch Neuroscience Institute (SLMBNI), part of ... an interim basis since 2016. , Cheerag D. Upadhyaya, MD. M.Sc., FAANS joins ...
(Date:7/24/2017)... ... July 24, 2017 , ... BayMark Health Services has ... Services Administration’s (SAMHSA) State Targeted Response to the Opioid Crisis program. The ... facilitate the development of a hub and spoke model for opioid treatment in ...
(Date:7/24/2017)... ... 2017 , ... Peruvian Ayahuasca retreat, East West Lodge, announced ... and divided between two full-time university students enrolled in U.S. or Canadian accredited ... apply for the scholarship, students are asked to submit an essay between 750 ...
(Date:7/24/2017)... CLARA, CA (PRWEB) , ... July 24, 2017 , ... ... and financial organizations, today announced it has partnered with WALLIX to expand ... Special Publication 800-171 . , There are a number of ways to address the ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... July 12, 2017 CarpalAID is a revolutionary new product ... surgery. Carpal tunnel syndrome affects more than 8 million ... the rate of men. The common methods of treating CTS are ... uncomfortable hand braces or gloves. ... CarpalAID is a clear patch worn on ...
(Date:7/11/2017)... July 11, 2017 Zymo Research Corp., also known as ,The ... quantify biological aging in a precise manner using the myDNAge ™ ... , a professor of human genetics and biostatistics at the David ... Public Health , Zymo Research,s proprietary DNAge ™ technology is used ... ...
(Date:7/11/2017)... , July 11, 2017  The global market for ... of approximately $394.1 million in 2016.  Although in early ... solid growth, in particular as a result of the ... and the recent introduction of a significant number of ... less-invasive testing of tumor biomarkers to guide treatment decisions. ...
Breaking Medicine Technology: